MERSANA THERAPEUTICS INC. - COMMON STOCK

Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

26 Apr 2023 15:05:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

13 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Statement About SVB

10 Mar 2023 18:10:38 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

02 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

25 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

06 Jan 2023 06:00:18 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

22 Dec 2022 15:05:10 By Nasdaq GlobeNewswire

European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

14 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Jefferies London Healthcare Conference

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

07 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2022 15:05:00 By Nasdaq GlobeNewswire